The opinion is not binding, was adopted by twenty votes for, twelve against and one abstention. For its part, the European EMA has no plans to comment on their security until September, unless the FDA decided to remove it before.
Both agencies are investigating the safety of the drug, although the American was more lax in their technical specifications and in the prospectus, we do warn of the risk of myocardial micardio. In Europe, this drug for type 2 diabetes is specifically contraindicated in patients with heart failure or acute coronary syndrome.
The Portuguese Bial acquires Italian laboratory Sarm
Bial Portuguese pharmaceutical group, the largest market Luso, which exports its drugs more than forty countries and is present in Spain through a production center and another R & D in Bilbao, acquired last week Sarm Italian laboratory specializing in allergy immunotherapy. The new company, to be called Bial-Sarm, seek to grow through the presence in countries including Spain is.
Oryzon announced an investment of 6.5 billion in R & D
Oryzon biotechnology company, a spin off of the Centro Superior de Investigaciones CientÃficas (CSIC) and University of Barcelona, \u200b\u200bannounced last week its investment figures for next year. Among them, spending 6.5 million euros in R & D. The research projects will focus on two major areas, cancer and neurodegenerative disease related.
Ferrer gave his library with a NGO for the development of antimalarial drugs
The laboratory Ferrer and Medicines for Malaria Venture (MMV), a non-profit organization, signed an agreement last week that the company will open its MMV perform chemical library for screening and identifying new compounds that could become treatments for malaria. This agreement will allow the Eskitis Institute for Cellular and Molecular Therapies at Griffith University, Brisbane (Australia).
http://www.correofarmaceutico.com/2010/07/19/farmacologia/en-breve-1
Both agencies are investigating the safety of the drug, although the American was more lax in their technical specifications and in the prospectus, we do warn of the risk of myocardial micardio. In Europe, this drug for type 2 diabetes is specifically contraindicated in patients with heart failure or acute coronary syndrome.
The Portuguese Bial acquires Italian laboratory Sarm
Bial Portuguese pharmaceutical group, the largest market Luso, which exports its drugs more than forty countries and is present in Spain through a production center and another R & D in Bilbao, acquired last week Sarm Italian laboratory specializing in allergy immunotherapy. The new company, to be called Bial-Sarm, seek to grow through the presence in countries including Spain is.
Oryzon announced an investment of 6.5 billion in R & D
Oryzon biotechnology company, a spin off of the Centro Superior de Investigaciones CientÃficas (CSIC) and University of Barcelona, \u200b\u200bannounced last week its investment figures for next year. Among them, spending 6.5 million euros in R & D. The research projects will focus on two major areas, cancer and neurodegenerative disease related.
Ferrer gave his library with a NGO for the development of antimalarial drugs
The laboratory Ferrer and Medicines for Malaria Venture (MMV), a non-profit organization, signed an agreement last week that the company will open its MMV perform chemical library for screening and identifying new compounds that could become treatments for malaria. This agreement will allow the Eskitis Institute for Cellular and Molecular Therapies at Griffith University, Brisbane (Australia).
http://www.correofarmaceutico.com/2010/07/19/farmacologia/en-breve-1
0 comments:
Post a Comment